Complement Component 3 Deficiency, Autosomal Recessive: Clinical Trials

1 trial for Complement Component 3 Deficiency, Autosomal Recessive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Completed 1

Follow Complement Component 3 Deficiency, Autosomal Recessive: new trials by email Literature Review of Complement Component 3 Deficiency, Autosomal Recessive trials Research Report on Complement Component 3 Deficiency, Autosomal Recessive

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Eculizumab - Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
Phase 3CompletedCedars-Sinai Medical Center362012-11-012021-05-03

Narrower conditions

Ventricular Dysfunction, Left (1)

Broader conditions

Cardiovascular Diseases (1)  ·  Heart Diseases (1)  ·  Ventricular Dysfunction (1)

Interventions

eculizumab (1)

Sponsors

Cedars-Sinai Medical Center (1)

Countries

United States (1)

Top investigators

Jignesh Patel, M.D., Ph.D. (1)

Results publications

PMID 33251691, PMID 37182818